Ambroxol ( DrugBank: Ambroxol )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	4
19	ライソゾーム病	7

6. パーキンソン病

臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05287503 (ClinicalTrials.gov)	February 15, 2022	28/1/2022	Ambroxol as a Disease-modifying Treatment in GBA-PD	Ambroxolas a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associate ...	Parkinson Disease;GBA Gene Mutation	Drug: Ambroxol Hydrochloride;Drug: Placebo	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	University of Campania Luigi Vanvitelli;IRCCS National Neurological Institute C. Mondino Foundation	Recruiting	21 Years	80 Years	All	60	Phase 2	Italy
2	NCT02941822 (ClinicalTrials.gov)	December 2016	5/9/2016	Ambroxol in Disease Modification in Parkinson Disease	A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerabili ...	Parkinson Disease	Drug: Ambroxol	University College, London	The Cure Parkinson's Trust	Completed	40 Years	80 Years	All	23	Phase 2	United Kingdom
3	EUCTR2015-002571-24-GB (EUCTR)	14/10/2016	12/02/2019	A Pilot Study to Evaluate the Safety, Tolerability (any side effects of the drug) and Pharmacodynami ...	A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerabili ...	Parkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: AMBROSAN 60mg Tablets Product Name: Ambroxol INN or Proposed INN: Ambroxol hydrochloride	Joint Research Office	NULL	Not Recruiting			Female: yes Male: yes	20	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United Kingdom
4	NCT02914366 (ClinicalTrials.gov)	November 2015	8/9/2016	Ambroxol as a Treatment for Parkinson's Disease Dementia	Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia	Parkinson's Disease Dementia	Drug: Ambroxol;Other: Placebo	Lawson Health Research Institute	Weston Brain Institute;University of Western Ontario, Canada;London Health Sciences Centre	Recruiting	50 Years	N/A	All	75	Phase 2	Canada

First Previous1Next Last

19. ライソゾーム病

臨床試験数 : 854 / 薬物数 : 716 - (DrugBank : 105) / 標的遺伝子数 : 70 - 標的パスウェイ数 : 191

diseases per page:

Showing 1 to 7 of 7 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2051210024	10/06/2021	11/05/2021	Investigation of the Food Effect on the Pharmacokinetics of JT408T	Investigation of the Food Effect on the Pharmacokinetics of JT408T	Improvement of neurological symptoms of Gaucher's disease	1) After fasting, administer 400 mg of ambroxolhydrochloride orally in a single dose. 2) After meals, ...	Ioroi Minoru	NULL	Not Recruiting	>= 20age old	< 35age old	Male	16	Phase 1	Japan
2	JPRN-jRCTs061190017	21/11/2019	26/09/2019	Japan-Ambroxol Chaperone Study	2 cohort, Non-randomized, Multi-site Study to Evaluate the Efficacy and Safety of Chaperone Therapy ...	Neuronopathic Gaucher disease	Ambroxol will be given.	Narita Aya	NULL	Recruiting	Not applicable	Not applicable	Both	25	Phase 3	Japan
3	JPRN-JMA-IIA00421	07/05/2019	26/04/2019	Phase II/III Study to Evaluate the Efficacy and Safety of Chaperone Therapy with AmbroxolHydrochlori ...	Phase II/III Study to Evaluate the Efficacy and Safety of Chaperone Therapy with AmbroxolHydrochlori ...	Neuronopathic Gaucher disease	Intervention type:DRUG. Intervention1:ADMINISTRATION, Dose form:TABLET, Route of administration:ORAL ...	Tottori University Hospital, Departrment of Child Neurology	NULL	Completed	No Limit	No Limit	BOTH	3	Phase 2-3	Japan
4	NCT03950050 (ClinicalTrials.gov)	March 1, 2019	6/8/2018	AmbroxolTherapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replaceme ...	AmbroxolTherapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replaceme ...	Gaucher Disease, Type 1	Drug: Ambroxol	Shaare Zedek Medical Center	NULL	Recruiting	18 Years	75 Years	All	60	Phase 2	Israel
5	NCT01463215 (ClinicalTrials.gov)	December 2012	27/10/2011	Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease	An Open-Label, Dose Escalation With 2 Dose Levels, Proof-of-Concept Clinical Trial of Ambroxolfor th ...	Type I Gaucher Disease	Drug: Ambroxol	Exsar Corporation	NULL	Suspended	16 Years	N/A	Both	20	Phase 1/Phase 2	United States
6	JPRN-UMIN000009392	2012/11/24	24/11/2012	An Open-Label, Dose Escalation, Proof-of-Concept Clinical Trial of Chaperone therapy of Neuronopathi ...		Neuronopathic Gaucher disease	Ambroxol at a dose level of 25 mg/kg/day (upper limit: 1g/day) will be given by mouth for 6 months.	Tottori University, Faculty of Medicine, Institute of Neurological Science	NULL	Recruiting	Not applicable	Not applicable	Male and Female	5	Phase 2,3	Japan
7	JPRN-jRCTs061180090	16/03/2010	22/03/2019	Chaperone therapy of Neuronopathic Gaucher Disease with Ambroxol	An Open-Label, Dose Escalation, Proof-of-Concept Clinical Trial of Chaperone therapy of Neuronopathi ...	Neuronopathic Gaucher disease Gaucher disease, Pharmacological chaperone therapy, ambroxol;D005776	Ambroxolat a dose level of 25 mg/kg/day (upper limit: 1300mg/day) will be given by mouth for 6 month ...	Maegaki Yoshihiro	NULL	Not Recruiting	Not applicable	Not applicable	Both	25	Phase 2	Japan

First Previous1Next Last

先頭へ